Shopping Cart 0
Cart Subtotal
AED 0

Oncobiologics Inc (ONS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Oncobiologics Inc (Oncobiologics) is a clinical stage biopharmaceutical company that identifies, develops, manufactures and commercializes biosimilar therapeutics in the areas of immunology and oncology. The company's pipeline products include ONS-3010, an adalimumab biosimilar intended for rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease and ulcerative colitis; and ONS-1045, a bevacizumab (Avastin) biosimilar intended to treat non-squamous non-small cell lung cancer. The company also develops various preclinical biosimilar product candidates including ONS-1050, a trastuzumab biosimilar that interferes with human epidermal growth factor receptor 2; ONS-4010, a biosimilar to denosumab; and ONS-3040, a biosimilar to ustekinumab. It develops products through strategic collaborations and partnerships with biotechnology and pharmaceutical companies. Oncobiologics is headquartered in Cranbury, New Jersey, the US.

Oncobiologics Inc (ONS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Oncobiologics Raises Additional USD13 Million in Venture Financing 12

Oncobiologics Raises USD31 Million in Financing Round 13

Partnerships 14

Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14

Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15

Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17

Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18

Licensing Agreements 19

Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19

Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20

Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21

Ipca Labs Amends Licensing Agreement with Oncobiologics 22

Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23

Equity Offering 24

Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24

Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25

Oncobiologics Plans to Raise Funds through Public Offering of Shares 26

Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27

Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28

Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30

Oncobiologics Raises USD35 Million in IPO of Units 31

Oncobiologics to Raise USD5 Million in Private Placement of Units 33

Oncobiologics Raises USD4 Million in Private Placement of Shares 34

Oncobiologics Raises USD7 Million in Private Placement of Shares 35

Debt Offering 36

Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36

Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37

Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40

Oncobiologics Inc-Key Competitors 41

Oncobiologics Inc-Key Employees 42

Oncobiologics Inc-Locations And Subsidiaries 43

Head Office 43

Recent Developments 44

Financial Announcements 44

Aug 14, 2018: Oncobiologics povides business update and reports third quarter financial results for fiscal 2018 44

May 15, 2018: Oncobiologics Announces Second Quarter Financial Results for Fiscal 2018 45

Feb 14, 2018: Oncobiologics Reports Q1 Fiscal 2018 Financial Results 46

Corporate Communications 49

Aug 02, 2018: Oncobiologics appoints Lawrence A. Kenyon as president and CEO 49

Jul 11, 2018: Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements 50

Apr 17, 2018: Oncobiologics Appoints Randy Thurman To Board Of Directors 51

Mar 27, 2018: Oncobiologics Names Dr. Joerg Windisch As Board Director 52

Feb 13, 2018: Oncobiologics Receives Positive Nasdaq Listing Determination 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Oncobiologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncobiologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oncobiologics Raises Additional USD13 Million in Venture Financing 12

Oncobiologics Raises USD31 Million in Financing Round 13

Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14

Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15

Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17

Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18

Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19

Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20

Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21

Ipca Labs Amends Licensing Agreement with Oncobiologics 22

Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23

Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24

Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25

Oncobiologics Plans to Raise Funds through Public Offering of Shares 26

Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27

Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28

Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30

Oncobiologics Raises USD35 Million in IPO of Units 31

Oncobiologics to Raise USD5 Million in Private Placement of Units 33

Oncobiologics Raises USD4 Million in Private Placement of Shares 34

Oncobiologics Raises USD7 Million in Private Placement of Shares 35

Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36

Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37

Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40

Oncobiologics Inc, Key Competitors 41

Oncobiologics Inc, Key Employees 42

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Oncobiologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Oncobiologics Inc (Oncobiologics) is a clinical stage biopharmaceutical company that identifies, develops, manufactures and commercializes biosimilar therapeutics in the areas of immunology and oncology. The company's pipeline products include ONS-3010, an adalimumab biosimilar intended for rheumatoid arthritis, psoriasis, ankylosing spondylitis, psoriatic arthritis, Crohn's disease and ulcerative colitis; and ONS-1045, a bevacizumab (Avastin) biosimilar intended to treat non-squamous non-small cell lung cancer. The company also develops various preclinical biosimilar product candidates including ONS-1050, a trastuzumab biosimilar that interferes with human epidermal growth factor receptor 2; ONS-4010, a biosimilar to denosumab; and ONS-3040, a biosimilar to ustekinumab. It develops products through strategic collaborations and partnerships with biotechnology and pharmaceutical companies. Oncobiologics is headquartered in Cranbury, New Jersey, the US.

Oncobiologics Inc (ONS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deal Details 12

Venture Financing 12

Oncobiologics Raises Additional USD13 Million in Venture Financing 12

Oncobiologics Raises USD31 Million in Financing Round 13

Partnerships 14

Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14

Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15

Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17

Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18

Licensing Agreements 19

Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19

Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20

Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21

Ipca Labs Amends Licensing Agreement with Oncobiologics 22

Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23

Equity Offering 24

Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24

Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25

Oncobiologics Plans to Raise Funds through Public Offering of Shares 26

Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27

Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28

Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30

Oncobiologics Raises USD35 Million in IPO of Units 31

Oncobiologics to Raise USD5 Million in Private Placement of Units 33

Oncobiologics Raises USD4 Million in Private Placement of Shares 34

Oncobiologics Raises USD7 Million in Private Placement of Shares 35

Debt Offering 36

Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36

Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37

Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40

Oncobiologics Inc-Key Competitors 41

Oncobiologics Inc-Key Employees 42

Oncobiologics Inc-Locations And Subsidiaries 43

Head Office 43

Recent Developments 44

Financial Announcements 44

Aug 14, 2018: Oncobiologics povides business update and reports third quarter financial results for fiscal 2018 44

May 15, 2018: Oncobiologics Announces Second Quarter Financial Results for Fiscal 2018 45

Feb 14, 2018: Oncobiologics Reports Q1 Fiscal 2018 Financial Results 46

Corporate Communications 49

Aug 02, 2018: Oncobiologics appoints Lawrence A. Kenyon as president and CEO 49

Jul 11, 2018: Oncobiologics Regains Compliance with Applicable Nasdaq Listing Requirements 50

Apr 17, 2018: Oncobiologics Appoints Randy Thurman To Board Of Directors 51

Mar 27, 2018: Oncobiologics Names Dr. Joerg Windisch As Board Director 52

Feb 13, 2018: Oncobiologics Receives Positive Nasdaq Listing Determination 53

Appendix 54

Methodology 54

About GlobalData 54

Contact Us 54

Disclaimer 54


List Of Figure

List of Figures

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Oncobiologics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Oncobiologics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Oncobiologics Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Oncobiologics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Oncobiologics Raises Additional USD13 Million in Venture Financing 12

Oncobiologics Raises USD31 Million in Financing Round 13

Oncobiologics And inVentiv Health Enter Into Agreement To Develop Biosimilars 14

Zhejiang Huahai Pharma Amends its Co-Development Agreement with Oncobiologics 15

Viropro Enters Into Agreement With Oncobiologics For Biosimilar Monoclonal Antibody Products 17

Oncobiologics Enters Into Agreement With Xoma To Develop Novel Botherapeutics 18

Oncobiologics Enters into Licensing Agreement with GMS Tenshi 19

Oncobiologics Enters into Licensing Agreement with Liomont to Develop Biosimilar Monoclonal Antibody 20

Ipca Labs Enters into Licensing Agreement with Oncobiologics for ONS-1050 21

Ipca Labs Amends Licensing Agreement with Oncobiologics 22

Oncobiologics Enters Into Licensing Agreement With Boston Oncology For Biosimilar Therapies 23

Oncobiologics Raises USD7.5 Million in Second Tranche of Private Placement of Shares and Warrants 24

Oncobiologics Raises USD7.5 Million in First Tranche of Private Placement of Shares and Warrants 25

Oncobiologics Plans to Raise Funds through Public Offering of Shares 26

Oncobiologics Raises USD25 Million in Private Placement of Preferred Shares and Warrants 27

Oncobiologics Raises USD0.4 Million in First Tranche of Private Placement of Shares 28

Oncobiologics to Raise USD6 Million in Private Placement of Shares upon Exercise of Warrants 30

Oncobiologics Raises USD35 Million in IPO of Units 31

Oncobiologics to Raise USD5 Million in Private Placement of Units 33

Oncobiologics Raises USD4 Million in Private Placement of Shares 34

Oncobiologics Raises USD7 Million in Private Placement of Shares 35

Oncobiologics Raises USD1.5 Million in Third and Final Tranche of Private Placement of Notes and Warrants Due 2017 36

Oncobiologics Raises USD1.7 Million in Second Tranche of Private Placement of Notes and Warrants Due 2017 37

Oncobiologics Raises USD8.4 Million in First Tranche of Private Placement of Notes and Warrants Due 2017 38

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2015 39

Oncobiologics Raises USD2 Million in Private Placement of 12% Notes Due 2016 40

Oncobiologics Inc, Key Competitors 41

Oncobiologics Inc, Key Employees 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Oncobiologics Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.